{
  "schema": "nmd-vcell-experiment-plan-registry/1.0",
  "updated": "2026-09-15",
  "deployment_state": "LOCAL_CANDIDATE_NOT_PRODUCTION",
  "experiment_plan_schema": "/resource/api/v2/experiment_plan.schema.json",
  "record_count": 1,
  "execution_authorized_count": 0,
  "registration_ready_count": 0,
  "records": [
    {
      "plan_id": "EXPERIMENT-PLAN:DMD:ZNF133:CRISPRI:48H:FUSION_AND_MOLECULAR_RESPONSE:V1",
      "version": "1.0.0",
      "lifecycle_track": "TRUTH_GENERATION",
      "overall_state": "DRAFT_BLOCKED_OPEN_NUMERIC_AND_AUTHORITY_GATES",
      "source_answer_id": "ANSWER:Q2:DMD:PROLIFERATING_MYOBLAST:CRISPRI:ZNF133:48H:FUSION_AND_MOLECULAR_RESPONSE:V1",
      "source_answer_sha256": "5f3a8032becd59203d545af781bf5ac28e0d2a9b36716ce6e6e3ef1c7e4b80c4",
      "study_card_id": "SC:v1.2.0-measured-dmd-evidence:ZNF133:1.5-DRAFT",
      "study_card_path": "/resource/study-card/ZNF133",
      "study_card_source_sha256": "844ebfb33670f731dbfb5ecb4e3f3507b58402116c18968f461e37c78c0b49f9",
      "question": {
        "question_schema": "nmd-vcell-research-question/2.0",
        "query_version": "2",
        "question_id": "Q2:DMD:PROLIFERATING_MYOBLAST:CRISPRI:ZNF133:48H:FUSION_AND_MOLECULAR_RESPONSE:SINGLE",
        "disease": "DMD",
        "cell_state": "PROLIFERATING_MYOBLAST",
        "perturbation": "CRISPRI",
        "target": "ZNF133",
        "targets": [
          "ZNF133"
        ],
        "time": "48H",
        "endpoint": "FUSION_AND_MOLECULAR_RESPONSE",
        "study_mode": "SINGLE_TARGET"
      },
      "execution_authorized": false,
      "registration_ready": false,
      "prediction_required": false,
      "gate_summary": {
        "ready": 6,
        "partial": 2,
        "open": 6,
        "total": 14
      },
      "gates": [
        {
          "gate_id": "GATE:QUESTION_SCOPE",
          "label": "Question scope",
          "class": "READY",
          "state": "READY_REGISTERED_ANSWER",
          "source": "ANSWER:Q2:DMD:PROLIFERATING_MYOBLAST:CRISPRI:ZNF133:48H:FUSION_AND_MOLECULAR_RESPONSE:V1",
          "requirement": "Preserve the exact disease, cell state, perturbation, target, time and endpoint identity."
        },
        {
          "gate_id": "GATE:BIOLOGICAL_SCOPE",
          "label": "Disease, cell, target, time and endpoint",
          "class": "READY",
          "state": "READY_AS_DRAFT",
          "source": "Q2:DMD:PROLIFERATING_MYOBLAST:CRISPRI:ZNF133:48H:FUSION_AND_MOLECULAR_RESPONSE:SINGLE",
          "requirement": "Freeze the query-selected scope at registration; do not generalize beyond it."
        },
        {
          "gate_id": "GATE:PRIMARY_ESTIMAND",
          "label": "Primary estimand",
          "class": "PARTIAL",
          "state": "PARTIAL_REQUIRES_ENDPOINT_SCALE_AND_NUMERIC_EFFECT",
          "source": "SC:v1.2.0-measured-dmd-evidence:ZNF133:1.5-DRAFT",
          "requirement": "Choose the primary endpoint scale and freeze the minimally important numeric effect with units."
        },
        {
          "gate_id": "GATE:INFERENTIAL_UNIT",
          "label": "Inferential unit",
          "class": "READY",
          "state": "READY_AS_DRAFT",
          "source": "SC:v1.2.0-measured-dmd-evidence:ZNF133:1.5-DRAFT",
          "requirement": "Independent biological replicate or independently generated perturbation unit; cells within one aggregate are not inferential replicates."
        },
        {
          "gate_id": "GATE:CONTROLS",
          "label": "Comparator and controls",
          "class": "READY",
          "state": "READY_AS_DRAFT",
          "source": "SC:v1.2.0-measured-dmd-evidence:ZNF133:1.5-DRAFT",
          "requirement": "Non-targeting control. Positive assay control. Mock delivery control when delivery itself can affect phenotype. Target-engagement and viability controls."
        },
        {
          "gate_id": "GATE:REPLICATION",
          "label": "Replication and sample size",
          "class": "OPEN",
          "state": "OPEN_POWER_CALCULATION",
          "source": "SC:v1.2.0-measured-dmd-evidence:ZNF133:1.5-DRAFT",
          "requirement": "Use the 3–6 replicate range only for a variance pilot; freeze final n after assay variance and minimally important effect are available."
        },
        {
          "gate_id": "GATE:RANDOMIZATION",
          "label": "Randomization and blocking",
          "class": "PARTIAL",
          "state": "PARTIAL_SEQUENCE_NOT_GENERATED",
          "source": "SC:v1.2.0-measured-dmd-evidence:ZNF133:1.5-DRAFT",
          "requirement": "Randomize Independent culture well or biological replicate, not individual cells.; retain blocks for Donor/isogenic pair. Differentiation batch. Plate and reagent identity.; generate and freeze the allocation sequence."
        },
        {
          "gate_id": "GATE:BLINDING",
          "label": "Blinding",
          "class": "OPEN",
          "state": "OPEN_NOT_SPECIFIED",
          "source": "SC:v1.2.0-measured-dmd-evidence:ZNF133:1.5-DRAFT",
          "requirement": "Declare who is blinded during acquisition, QC, endpoint extraction and primary analysis."
        },
        {
          "gate_id": "GATE:NUMERIC_QC",
          "label": "Numeric assay QC",
          "class": "OPEN",
          "state": "OPEN_NUMERIC_THRESHOLDS",
          "source": "SC:v1.2.0-measured-dmd-evidence:ZNF133:1.5-DRAFT",
          "requirement": "Target-engagement threshold must be numeric and frozen. Viability floor and image-quality thresholds must be numeric and frozen."
        },
        {
          "gate_id": "GATE:EFFECT_MARGINS",
          "label": "Effect and equivalence margins",
          "class": "OPEN",
          "state": "OPEN_NUMERIC_VALUES_AND_UNITS",
          "source": "SC:v1.2.0-measured-dmd-evidence:ZNF133:1.5-DRAFT",
          "requirement": "Required before registration; derive from assay biology or a justified pilot and store the numeric value with units. Required before interpreting a null result; store a symmetric or asymmetric numeric margin with units."
        },
        {
          "gate_id": "GATE:ANALYSIS",
          "label": "Analysis, multiplicity and missingness",
          "class": "READY",
          "state": "READY_AS_DRAFT",
          "source": "SC:v1.2.0-measured-dmd-evidence:ZNF133:1.5-DRAFT",
          "requirement": "Mixed-effects model with treatment fixed effect and donor/batch/reagent blocking; report reagent-specific estimates. Primary endpoint across the two reagents; secondary endpoints form a separate multiplicity family. Define exclusions before unblinding; report all missing units and reasons; do not single-impute primary outcomes without a prespecified sensitivity analysis."
        },
        {
          "gate_id": "GATE:STOP_AND_RELEASE",
          "label": "Stopping and complete release",
          "class": "READY",
          "state": "READY_AS_DRAFT",
          "source": "SC:v1.2.0-measured-dmd-evidence:ZNF133:1.5-DRAFT",
          "requirement": "Stop or classify as infeasible if a required numeric QC threshold fails. Do not interpret a nonsignificant result as no material effect without a negligible-effect interval. Do not change canonical candidate status automatically; require governed review. Release the frozen card, protocol identifiers, analysis code, complete denominators and results irrespective of direction; never overwrite the registered card."
        },
        {
          "gate_id": "GATE:REGISTRATION",
          "label": "Immutable registration",
          "class": "OPEN",
          "state": "OPEN_NOT_REGISTERED",
          "source": "/resource/api/v1.1/registered_studies.json",
          "requirement": "Resolve authority decisions, freeze the plan and deposit an immutable registered Study before execution."
        },
        {
          "gate_id": "GATE:OUTCOME_SLOT",
          "label": "Outcome return slot",
          "class": "OPEN",
          "state": "OPEN_EMPTY_LEDGER",
          "source": "/resource/api/v2/outcome_ledger.json",
          "requirement": "Append every qualifying outcome, including null, toxic, discordant, QC-failed and inconclusive results; never overwrite registration."
        }
      ],
      "design_contract": {
        "primary_endpoint": "One predeclared functional endpoint, with fusion as the query-selected endpoint",
        "secondary_endpoints": [
          "target engagement",
          "viability/toxicity",
          "directional transcriptomic response"
        ],
        "primary_estimand": "Between-condition mean difference (or prespecified ratio) in the primary functional endpoint at the frozen time point.",
        "inferential_unit": "Independent biological replicate or independently generated perturbation unit; cells within one aggregate are not inferential replicates.",
        "comparator_and_controls": [
          "Non-targeting control.",
          "Positive assay control.",
          "Mock delivery control when delivery itself can affect phenotype.",
          "Target-engagement and viability controls."
        ],
        "perturbation": "CRISPRi with at least two independent reagents where feasible",
        "planning_sample_size": "3–6 independent biological replicates per condition and reagent; final powered n remains open",
        "randomisation_unit": "Independent culture well or biological replicate, not individual cells.",
        "blocking_factors": [
          "Donor/isogenic pair.",
          "Differentiation batch.",
          "Plate and reagent identity."
        ],
        "statistical_model": "Mixed-effects model with treatment fixed effect and donor/batch/reagent blocking; report reagent-specific estimates.",
        "multiple_testing_family": "Primary endpoint across the two reagents; secondary endpoints form a separate multiplicity family.",
        "missing_data_rule": "Define exclusions before unblinding; report all missing units and reasons; do not single-impute primary outcomes without a prespecified sensitivity analysis.",
        "guide_concordance_rule": "Both reagents must agree in direction and neither may fail the engagement/QC gate; discordance is inconclusive.",
        "donor_replication_rule": "Direction must replicate beyond a single donor or isogenic pair before L4 escalation.",
        "stop_rules": [
          "Stop or classify as infeasible if a required numeric QC threshold fails.",
          "Do not interpret a nonsignificant result as no material effect without a negligible-effect interval.",
          "Do not change canonical candidate status automatically; require governed review."
        ],
        "data_release_plan": "Release the frozen card, protocol identifiers, analysis code, complete denominators and results irrespective of direction; never overwrite the registered card."
      },
      "unresolved_decisions": [
        "Freeze the perturbation direction and its causal, compensatory or accompanying rationale.",
        "Freeze the primary endpoint scale, minimally important effect and units.",
        "Freeze the negligible-effect margin and units before interpreting a null result.",
        "Estimate assay variance and complete the final sample-size calculation.",
        "Freeze numeric target-engagement, viability and image-quality thresholds.",
        "Generate the allocation sequence and declare blinding responsibilities.",
        "Name the experimental authority and create an immutable registration receipt."
      ],
      "outcome_slot": {
        "ledger_path": "/resource/api/v2/outcome_ledger.json",
        "state": "EMPTY_PENDING_REGISTERED_STUDY_AND_EXPERIMENT",
        "measured_outcome_count": 0
      },
      "claim_ceiling": "EXPERIMENT_DESIGN_ONLY",
      "does_not_imply": [
        "that execution is authorized",
        "that the draft is registered, immutable or powered",
        "that a DMD perturbation response has been predicted or measured",
        "that ZNF133 is beneficial, harmful or therapeutically ranked"
      ],
      "generated_by": [
        "PROCESS:EXPERIMENT_OS_BUILD:V201"
      ],
      "is_new_scientific_claim": false,
      "experiment_plan_sha256": "6b82836351f9f93d6d3f1d3932fa9436baceab58d39195b82efc9d76de139018"
    }
  ],
  "plan_set_sha256": "585084757bacf7e375833858755bfa35c397ef2df962ffc9e80ad36f528f018e"
}
